-

Consumer Watchdog Attorneys at Hagens Berman Warn John Muir Patients of Potential Overbilling

Law firm says Bay Area patients of any John Muir hospital or emergency room may have been overbilled thousands of dollars for drug tests

SAN FRANCISCO--(BUSINESS WIRE)--Attorneys at consumer-rights law firm Hagens Berman are warning Bay Area residents they may have been wrongfully charged thousands of dollars by John Muir Health hospitals or emergency rooms for drug tests for illicit drug use.

The unexpected charges for drug tests from John Muir Health amount to upwards of $6,000, according to attorneys. Even patients with insurance are left with huge co-pays and deductibles for services they did not request or consent to having performed.

Attorneys at the law firm say patients may have rights to their money back under consumer-protection laws.

If you received large and unexpected charges for a drug test after visiting a John Muir Health location, find out your rights to potential repayment.

Hagens Berman’s representation of consumers has earned it national recognition, and the firm has achieved more than $320 billion in settlements for its clients since its founding.

Your Patient Rights Against Billing Fraud

According to the firm, expensive and unexpected bills for drug tests may constitute fraud, and patients of John Muir hospitals may have consumer rights against these predatory billing practices.

Attorneys say all John Muir Health locations are under investigation, including Concord Medical Center, Walnut Creek Medical Center, Behavioral Health Center, San Ramon Regional Medical Center (Partner Hospital), Urgent Care Centers, Berkeley Urgent Care Center, Brentwood Urgent Care Center, Concord Urgent Care Center, San Ramon Urgent Care Center, Walnut Creek Urgent Care Center and Aspen Surgery Center.

Find out more about the patient billing fraud investigation against John Muir Health.

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation law firm with a tenacious drive for achieving real results for those harmed by corporate negligence and fraud. Since its founding in 1993, the firm’s determination has earned it numerous national accolades, awards and titles of “Most Feared Plaintiff’s Firm,” MVPs and Trailblazers of class-action law. More about the law firm and its successes can be found at www.hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contacts

Ashley Klann
pr@hbsslaw.com
206-268-9318

Hagens Berman


Release Summary
Hagens Berman attorneys warn Bay Area residents they may have been charged thousands by John Muir Health hospitals or ERs for illicit drug use tests.
Release Versions

Contacts

Ashley Klann
pr@hbsslaw.com
206-268-9318

More News From Hagens Berman

Hub Group (HUBG) Shares Crater Amid Admitted Improper Accounting – Hagens Berman

SAN FRANCISCO--(BUSINESS WIRE)--Hub Group, Inc. (NASDAQ: HUBG) shares fell over 27% during trading on Feb. 6, 2026, after the company filed a report with the SEC that its quarterly reports going back to March 31, 2025, “should no longer be relied upon.” These events prompted Hagens Berman, a national shareholder rights law firm, to investigate whether Hub Group may have intentionally misled investors about whether its financial statements are consistent with relevant accounting rules. The firm...

Hagens Berman: Lawsuit Details Excessive Harassment and Employment Retaliation at Snohomish County Juvenile Detention Center

SEATTLE--(BUSINESS WIRE)--Snohomish Co. has been sued for retaliation after a former officer reported harassment at Denney Juvenile Justice Center, according to Hagens Berman....

Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing

SAN FRANCISCO--(BUSINESS WIRE)--Hagens Berman, a national shareholder rights law firm, is investigating whether Corcept Therapeutics Inc. (NASDAQ: CORT) misled investors about relacorilant’s efficacy and commercial prospects. Corcept is under renewed scrutiny after Reuters reported on Jan. 30, 2026, that the FDA had warned the company “on several occasions” not to submit its application for relacorilant, its proposed treatment for hypercortisolism. The report sent Corcept shares down, wiping ou...
Back to Newsroom